Investigating new agents to help achieve HIV remission
Official title: Exploration of novel block-and-lock agents alone and in combination for HIV remission in humanized mice
Funded at University of Florida · NIH-11046602 · Data updated 2026-11-12
This study is testing new ways to help people with HIV by using special treatments that could reduce the virus in their bodies without needing to take daily medication, aiming for a long-lasting solution that could improve their health and comfort.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | March 20, 2023 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $835,484 |
| NIH project number | 5R01AI177327-03 |
| Project ID | NIH-11046602 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are currently on antiretroviral therapy and seeking alternatives for long-term management.
✕Less likely to help
Patients who are not living with HIV or those who are not adherent to antiretroviral therapy may not benefit from this research.
What this research studies
This research explores the use of novel agents that inhibit HIV-1 transcription, aiming to reduce the virus's presence in the body without the need for daily antiretroviral therapy. By focusing on a combination of existing medications and new approaches, the study seeks to achieve long-term suppression of HIV through a method known as 'block-and-lock.' Patients may benefit from a potential functional cure that minimizes the chronic inflammation and immune activation associated with HIV. The research will utilize humanized mouse models to test the effectiveness of these agents.
Why it matters
Potential benefit: If successful, this research could lead to a functional cure for HIV, significantly improving the quality of life for patients living with the virus.
How similar studies have gone: While the approach of using transcriptional inhibitors is promising, it is still largely untested in clinical settings, making this research a novel exploration.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Valente, Susana T — University of Florida
- Study coordinator: Valente, Susana T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.